



RDTTM

RAPID DOSE THERAPEUTICS

INVESTOR PRESENTATION | OCTOBER 2019

CSE: DOSE

Disclaimer

This document is a presentation (the “Corporate Presentation”) of general background information about the current activities of Rapid Dose Therapeutics (RDT) Canada Inc. (“RDT”) as of September 3, 2019. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. This Corporate Presentation should be considered, with or without professional advice, when considering the business and prospects of RDT. This Corporate Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this Corporate Presentation who are considering acquiring securities and assessing the business of RDT are reminded that any such assessment must not be made on the basis of the information contained in this Corporate Presentation but are referred to the entire body of publicly disclosed information regarding RDT.

Cautionary Note Regarding Forward-Looking Statements: Certain statements in this Corporate Presentation contain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Any statements that are contained in this Corporate Presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often, although not always, identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this Corporate Presentation include, but are not limited to statements with respect to growth of the QuickStrip™ brand, consumer adoption rates, distribution plans of RDT’s customers, future market growth rates, geographic expansion plans and financial projections. The financial projections in this Corporate Presentation are provided for the purpose of assisting readers to evaluate RDT’s potential financial prospects under various revenue scenarios and such financial projections may not be appropriate for any other purpose. Such forward-looking statements, including, without limitation, in respect of the delivery of products using the QuickStrip™ product delivery method, express, as at the date of this Corporate Presentation, the plans, estimates, forecasts, projections, expectations or beliefs of RDT as to future events or results and are believed to be reasonable based on information currently available to RDT management. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this Corporate Presentation, including assumptions regarding expected growth, results of operations, performance, industry trends and growth opportunities for RDT and the markets in does business in. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical and recreational marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada and the U.S. generally; income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that the forward-looking statements contained herein, although considered reasonable by management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this Corporate Presentation are expressly qualified by this cautionary note. These forward-looking statements are made as of the date of this Corporate Presentation and RDP assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as expressly required by applicable law.

At a glance

Founded: May 3, 2017

Number of employees: 20

Publicly Traded: as of December 17, 2018

Ticker symbol: CSE:DOSE

Shares Issued & Outstanding: 75,791,327 shares

Options outstanding: 4,426,000 @ \$0.82 expiring 2024

Share Fully Diluted: 80,217,327 (Escrowed shares 46,715,526)

Insider Ownership: 37%

Cash Resources (as at May 31, 2019): \$1,988,249



Experienced management team

Mark Upsdell

Chief Executive Officer

- Former Director, Global Strategy and Planning, CISCO
- Over 30 years experience providing strategic leadership in Fortune 500 companies within the technology sector
- Managed people, process, governance and tools — to enable global sales teams to drive a combined 11 billion in revenue.

Jason Lewis

SVP, Business Development

- An entrepreneurial executive with +28 years of hands-on expertise within the healthcare and pharmaceutical sectors.
- Previously Director of International Marketing Apotex, and VP of Marketforce a subsidiary of GSW.

Ian Fodie

Chief Financial Officer

- CA from New Zealand Institute
- Previously CFO of Green Growth Brands Ltd., CFO of First Bauxite Corporation and Lithium Americas Corp., President & CEO of Oriental Minerals Inc. (now Woulfe Mining Corp.), and CFO of Longview Capital Partners Inc. (now Resinco Capital Partners Inc.).

Kristina Shea

Marketing and Communications Director

- +25 years of experience in strategic leadership within marketing, branding, digital advertising, digital transformation and project management
- Worked with Fortune 500 companies — including consumer, financial and government sectors including RBC, UBS Wealth Management to beauty and wellness brands.

Doug Hyland

Manager Systems & Process

- CPA with +30 years
- Diverse strategic financial and business experience across multiple industries including manufacturing and distribution, financial services, technology, and the health industry.

Dr. Rina Carlini

Director, Research & Innovation

- Executive in science & technology innovation, commercialization and scaling tech ventures.
- Previous President & CEO at Haltech Regional Innovation Centre; Interim President at Cloud DX Canada, Principal & Nanotechnology Director at Xerox Canada.
- Inventor of 100 US patents, co-author of 20+ peer-reviewed research articles; and reviewer of government funding agencies (OCE, NSERC, CFI, MaRS).

Building a global brand

Game Changing Delivery

Rapid Dose Therapeutics, RDT, is a Canadian med-tech company providing a Managed Strip Service Program which enables proprietary drug delivery technologies designed to improve patient and consumer outcomes.

RDT provides a turnkey service program for product innovation, production, and consultation to the pharmaceutical, nutraceutical and cannabis industries. For more information, visit: rapid-dose.com

Mission

To create novel, convenient, enhanced rapid delivery therapeutics to improve healthcare outcomes for patients.



Addressing the cannabis market

QuickStrip™

Anytime, Anywhere™

QuickStrip™ precisely delivers active Ingredients using an orally dissolvable strip to deliver the therapeutic dose **directly into the blood stream.**

**Quick,
Convenient,
Precise, Discreet™**

RDT's proprietary delivery system and trademarked brand QuickStrip™ transforms how pharmaceutical, nutraceuticals and cannabis are consumed.

The
Smoke-Free
Choice™
for cannabis
consumers

RDT provides the proprietary QuickStrip™ technology under a Managed Strip Services Contract (MSS) – this enables a **recurring revenue model**



RDT verticals

RDT has three business divisions — delivering health and therapeutic applications.



Over the Counter (OTC) Nutraceuticals

- OTC product portfolio (NPN, Health Canada approved)
- QuickStrip™ Energy (Caffeine)
- QuickStrip™ B12
- QuickStrip™ Sleep (Melatonin)
- Other OTC products in the pipeline: QuickStrip™ Nicotine, Pain, Allergy, Vitamins
- Primary OTC targets for RDT are the large CDN US retail chains selling high volume consumer oriented products



Cannabis

- QuickStrip™ medical and recreational markets
- RDT licenses proprietary QuickStrip™ technology under a Managed Strip Services Contract (MSS) – this enables a **recurring revenue model**
- QuickStrip™ — The Quick, Convenient, Precise and Discreet™ smoke-free choice for consumers



Pharmaceutical

- Branded drug manufacturers seeking alternative delivery to expand or enhance products where rapid dosage or simplified delivery are important factors.
- Opportunity for branded products in mid-cycle, near patent expiry, or line extension.

RDT QuickStrip™ lifestyle nutraceuticals

Over the Counter (OTC) QuickStrip™ product portfolio
(NPN, Health Canada approved)

Distribution and e-commerce



ENERGY ⚡



VITAMIN B12 🍒




SLEEP 🌙

July 2019 – Twelve Month Distribution Agreement signed
for 10 European countries for US\$4 million

QuickStrip™ enhanced delivery

QuickStrip™ oral thin film delivers a precise dose of active medicinal ingredient directly into the blood stream – bypassing stomach degradation and first-pass metabolism in the liver.




Recently published research study* on delivery and bioavailability of Caffeine based QuickStrip™ film strips in mice showed:

- 30% greater bioavailability, as measured by area under the curve analysis (when compared to oral administration by gavage)
- QuickStrip™ delivery resulted in higher serum levels of caffeine at 1, 10, and 30 min (compared to gavage.)
- Rapid absorption of caffeine via QuickStrip™ delivery within 1 minute gave a rapid EEG signal suppression, stimulating the motor ability of mice.

RDT innovative technology

Film casting, slitting and packaging equipment are custom-designed for high-throughput production of QuickStrip™ oral film strips


- Remote production at our licensed global customer sites, through a **Managed Strip Service Agreement (MSSA)**.
- **White-label manufacturing (WLM)** at RDT headquarter site (Burlington, Ontario)



Recurring revenue business model



RDT charges a service fee to licensed cannabis producers and growers globally, for production of RDT's proprietary QuickStrip™ technology under a Managed Strip Service Agreement (MSSA)



Six signed (5-year) recurring revenue contracts
One signed (5-year) white label manufacturing contract

MSSA service-fee
for every strip produced above minimum quantity

Company milestones



Definitive contract
signed with agreement
with **Aphria Canada**

(Installed)



Definitive contract
signed with Flower
One for the state
of **Nevada**

(Installed)



Definitive contract signed
with agreement with
Aphria Germany



Definitive contract
signed with
Chemesis for the
state of California



Definitive contract
signed with
Chemesis for the
territory of Puerto Rico

(Installed)



Definitive contract
signed with
Chemesis for the
state of Michigan



Definitive contract
signed with Thrive
for white label
manufacturing in
Canada.

Company milestones




TOP 10 IN GROCERY

Top Ten New Product awarded by **Grocery Innovation Canada (GIC)** for non-food category



Patents pending in **US** and **Canada**



9 trademark applications filed in Canada and the USA



QuickStrip™ available for retail in hotel kiosks in Las Vegas for Nutraceuticals: Energy, B12 & Sleep









Expansion of operations for a further **40,000 sq ft. production** for **QuickStrip technology** and **pipeline products**



1 non-provisional PCT patent application filed, **6 provisional U.S. patent applications** filed

Research & development

 <p>Researching polymer thin film technology for oil-based therapeutics delivery</p> <p>(completed)</p>	 <p>EEG & behavioural study with QuickStrip™ delivery system</p> <p>(completed)</p>	 <p>Case Study of Vitamin B12 for IBS with major medical institutions in Canada</p>
 <p>Pre-clinical studies to investigate health outcomes of cannabis QuickStrip™</p>	 <p>Development of methods for total synthesis of high purity cannabinoids and derivatives</p>	 <p>Bioanalytical study of QuickStrip™ as a delivery vehicle for CBD</p>

Financial impact of MSS Agreements



RDT continues to perform under these signed MSS agreements. With internal testing of production systems nearing completion, RDT has commenced the **delivery of five QuickStrip™ production systems during the second quarter of FY2020** (FY2020 commences March 1, 2019) for installation and commissioning in RDT's customers' locations.

MSS agreements provide:

- **Contract signing fees**
- **Installation and commissioning fees**
- Per unit production fees with **contracted minimum revenues** over their respective terms.

As a result of the signed MSS agreements, RDT has received, as of May 31, 2019, initial payments amounting to **CDN\$1,016,000**

Canadian licensed manufacturer/reseller



Aphria secured
\$5.4MM
 private placement
 with RDT
7.2MM shares
 at **\$0.75**

- Research & development
- Clinical studies
- Manufacturing
- Marketing & sales

- High-quality genetics
- Expert Personnel
- Best practices
- Registered patient network
- Marketing & sales
- Global distribution channels

RDT Brand



Aphria-QuickStrip product distribution

Definitive agreement
 signed with RDT for
 exclusive **preferred**
global rights in Canada



Germany licensed manufacturing/reseller



Granted rights to license, manufacture, distribute and sell RDT's QuickStrip™ technology to the German cannabis market

- RDT and Aphria's agreement will support rapid global expansion of the QuickStrip™ brand and **accelerate QuickStrip™ consumer adoption into key European cannabis markets.**
- Aphria expects to produce and distribute CBD-only Quickstrips™ in Germany by Summer 2019.
- **Germany has a population of 82 million people — a population 2.5 times of Canada.**
- The BMO report below set the \$5 billion figure primarily based on an assumption that in seven years, 7.5% of sleep, anxiety and pain prescriptions in Germany will be replaced with cannabis — **opening up the cannabis market to approximately 26% of the overall German population.**¹

BMO's cannabis sector analysts forecast the German market could produce more than **\$5B in revenue for global cannabis producers.**¹

Reference: ¹ BMO: Canada Leads the Global Cannabis Paradigm Shift, May 2018.



Nevada manufacturing/reseller



Granted license to manufacture, distribute and sell QuickStrip™ delivery technology for the cannabis market in Nevada.

Nevada is one of the most lucrative cannabis markets in the United States, hosting 55 million tourists.

Nevada reported \$529.9MM in sales for all 2018 in cannabis sales and cannabis-related products.


- Flower One is the **largest cannabis cultivation greenhouse in Nevada** at 400,000 square feet.
- Flower One is the **largest cannabis processing and custom packaging facility in Nevada**, a 55,000 square foot operation.
- **Holds 9 licenses for medical and recreational cannabis cultivation and production in the state of Nevada.**
- Flower One's internal brand NLVO boasts a diverse **library of cannabis genetics which features over 50 unique strains** through its House Partner, NLV



Nevada cannabis market potential

Nevada's legal cannabis market
(US\$ in Millions)

Based on Colorado YoY Growth Rate



In Colorado

29.3%

3-year CAGR
Combined
Cannabis Sales
(2014 -2017)

In Nevada

\$529.9

2018 FY
Combined Sales
(1st Year)

*Includes both recreational and medical cannabis sales

Source: : State of Nevada, Department of Taxation and Statista 2018, Colorado Sales

California licensed manufacturer/reseller



- Established networks and **current retail operations underway in key markets in California.**
- Population of **California 39 million, larger than that of Canada**
- **QuickStrip™ is positioned for rapid growth with Chemesis** in the emerging US cannabis industry. Chemesis is a fully-compliant, fully licensed, first mover within California.



With nearly 40 million residents and more than a million medical marijuana patients, California's market represents about a third of the North American cannabis market.

Estimated cannabis California sales:



According to Arcview Market Research and BDS and Cowen & Co. analytics new report and Business Insider.



Puerto Rico licensed manufacturer/reseller



- Chemesis will continue to **expand the QuickStrip™ global footprint into the Puerto Rican and Latin American marketplace.**
- **Chemesis is currently retailing exclusive products in Puerto Rico which will include the QuickStrip™ brand to an available distribution of 600 dispensaries in both Puerto Rico and California**



Puerto Rico public health department anticipates registration of 100,000 registered patients by end of 2019.²


Legalized medical cannabis for qualifying health conditions in 2015, allows the use of medical cannabis derivatives.

Health Conditions include HIV, cancer, multiple sclerosis, migraines, anxiety, epilepsy, and other conditions.

² Reference: <http://www.salud.gov.pr/Documents/Cannabis/>



Global market outlook



Appendix

Corporate video





Rapid Dose Therapeutics Corp.
1121 Walkers Line, Unit 3A
Burlington ON L7N 2G4
P: 1.416.477.1052

For inquiries:

Ali Mahdavi
Managing Director
Spinnaker Capital Markets Inc.
am@spinnakercml.com
(416) 962-3300

CSE: DOSE